perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.01.24316555;](https://doi.org/10.1101/2024.11.01.24316555) this version posted November 4, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

The clots removed from ischaemic stroke patients by mechanical thrombectomy are amyloid in nature

Justine M. Grixti1 , Arun Chandran2 , Jan-Hendrik Pretorius3 , Melanie Walker4 , Alakendu Sekhar2 , Etheresia Pretorius1,**5* and Douglas B Kell1,5,6***

1 Department of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown St, Liverpool L69 7ZB, UK.

² Department of Neurology, The Walton Centre, Aintree University Hospital, Lower Lane, Fazakerley, Liverpool L9 7LJ, UK

³ Department of Economics, Stellenbosch University, Stellenbosch Private Bag X1 Matieland, 7602, South Africa

4 Department of Neurological Surgery, University of Washington, Seattle, WA 98104, USA

⁵ Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch Private Bag X1 Matieland, 7602, South Africa.

⁶ The Novo Nordisk Foundation Centre for Biosustainability, Building 220, Søltofts Plads 200, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.

Correspondence: [dbk@liv.ac.uk;](mailto:dbk@liv.ac.uk) resiap@sun.ac.za

Keywords: clotting – amyloid – fibrinaloid – proteomics – cross-seeding – fibrils - thrombectomy

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.01.24316555; this version posted November 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted

Table of contents

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Abstract

Ischemic stroke due to large vessel occlusion results from the blockage of a major cerebral artery by a clot; however, the origins and molecular composition of these clots remain poorly understood. Mechanical thrombectomy has become a standard treatment to remove obstructive clots, providing a unique opportunity to analyze their properties. We previously demonstrated that blood can clot into an amyloid-like form, generating fibrinaloid microclots (2–200 μm) that are highly resistant to fibrinolysis. In this study, archived clots from eight ischemic stroke patients with large vessel occlusion were examined, using samples stored in the Walton Centre Clot Bank in Liverpool, UK. All clots exhibited strong, heterogeneous amyloid staining, revealing a pervasive amyloid component. These findings represent a previously unreported characteristic of stroke clots, highlighting the potential for amyloid-targeted therapies to overcome their fibrinolytic resistance and providing a foundational new insight into ischaemic stroke pathophysiology and treatment.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Introduction

Stroke is the second leading cause of death worldwide, with an annual mortality rate exceeding 5 million persons (Donkor 2018; GBD 2019 Stroke Collaborators 2021; He et al. 2024; Powers 2020). In the more common ischaemic stroke, a blood vessel that supplies the brain becomes blocked by a clot or thrombus of some kind. A common and effective treatment is early enzymatic thrombolysis (Al-Ajlan et al. 2024; Gurman et al. 2015; Wardlaw et al. 2014), but this is not always possible and is not without a risk of inducing bleeding due to a lack of specificity of the relevant enzymes for fibrin (Emberson et al. 2014; Gurman et al. 2015; Röther et al. 2013; Zhong et al. 2024; Zubair and Sheth 2023). Endovascular mechanical thrombectomy to remove the blood clot responsible for the stroke is also now widespread (Campbell et al. 2019; El Tawil and Muir 2017; Hurford et al. 2020; Martin-Gutiérrez et al. 2024; Menon et al. 2019; Powers 2020), alone or additionally (Hammed et al. 2024; Heiferman et al. 2017; Rossi et al. 2022; Suzuki et al. 2021), and has the considerable scientific advantage that one can then study the clots so extracted (Huang and Bhaskar 2022; Martha et al. 2023; Walker et al. 2022). Some time ago, we discovered (Kell and Pretorius 2017; Pretorius et al. 2016) that blood can clot into an anomalous 'fibrin amyloid' or 'fibrinaloid' (Kell et al. 2022; Kell and Pretorius 2023; Nunes et al. 2022; Turner et al. 2023a) form that is relatively resistant to fibrinolysis. This would of course explain why such clots are not removed naturally (Desilles et al. 2022; Ho-Tin-Noé et al. 2023), but the clots there observed were microclots, whose equivalent diameter is commonly in the range 2-200 mm (Bergaglio et al. 2024; Dalton et al. 2024; Grobbelaar et al. 2022; Grobbelaar et al. 2021; Kell et al. 2022; Kruger et al. 2022; Nunes et al. 2022; Pretorius and Kell 2024; Pretorius et al. 2022; Schofield et al. 2024; Turner et al. 2023b). The availability of clots removed by thrombectomy here allows us to assess whether the mm-sized clots obtained following ischaemic stroke are 'normal', or whether they are in fact amyloid in character. We show that they are highly amyloid in nature.

We here assess the amyloid nature of the thrombectomised samples using standard fluorogenic staining. Of the many amyloid stains available (Chisholm and Hunter 2024), the most commonly used is thioflavin T, since its fluorescence is quenched (via an intramolecular bond rotation) (Amdursky et al. 2012) when in solution, but it is highly fluorescent when bound to an amyloid target (Biancalana and Koide 2010). Although a variety of other stains have been used to assess the clot morphology (and indeed origin) (Huang et al. 2022; Huang and Bhaskar 2022), we know of no study that has sought to stain for amyloid. This is what we do here, with striking results.

Methods

Thrombectomy, patient consenting, ethics and wax embedding.

Thrombectomies were performed using flow arrest with aspiration, and/or using the stent retriever technique, under general anaesthesia. The Walton center thrombectomy clot bank pilot feasibility trial formalized the clot collection and analysis process for patients with large vessel occlusion (LVO) stroke who had undergone thrombectomy.

The patient cohort enrolled in the clot bank feasibility trial were anonymously assigned a participant number (as in Table 1) and a proforma. Consent was obtained from next of kin (NOK) prior to thrombectomy completion.

For this specific analysis of clot samples obtained during the clotbank feasibility trial (IRAS 308223) a substantial amendment to cover the present studies was submitted to the Health research authority (HRA) for review by the Research Ethics Committee. A favourable opinion and approval for the amendment was obtained (REC reference 22/NW/0087) before the commencement of the formal analysis of the samples.

Study Specimen Collection:

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

During the procedure, the neuro-interventionalist collected the samples, which are removed during the thrombectomy procedure (samples collected between Monday-Thursday 9am-5pm). The retrieved thrombus materials (which would normally be discarded) were collected and stored in sample pots containing 10% formalin and transferred by a member of the neuroradiology team in a manner that did not delay or slow the thrombectomy procedure. The specimen pots were labelled according to the origin of the retrieved clot samples as proximal, distal, specific vessel information, 1st pass, 2nd pass and so on. The labelled formalin pots with patient addressographs were transferred to the Neuropathology lab and incorporated into the existing sample tracking system. Once the patient/personal consultee has consented /agreed to the retrieved clot being kept for future analysis, it was stored in the lab, registered as an 'LNBW' sample, and a unique study number generated. 8 out of the 31 patients who were asked (from nine different hospitals) consented during the recruitment period (7 March to 30 April, 2023), and these represent the study sample.

Within this sample, ages ranged from 58 to 88 years old, with all 8 patients being white Caucasian and all but one were males. None of the participants had a recent history of malignancies or infective endocarditis. Medical comorbidities ranged from hypertension, hyperlipidemia, gastric reflux, CABG, Atrial Fibrillation, diabetes, and smoking. All patients accepted by the center for thrombectomy had an mRS (modified Rankin scale) score (Wilson et al. 2005) between 0 and 2 (not shown). The majority of thrombi were found in the middle cerebral artery, with 100% of cases being treated using the flow arrest, aspiration, and stent technique. The longest time from onset of stroke to vessel recanalization seen in our cohort was 10 hours 32 minutes, which was seen in a patient where the stroke occurred overnight. In terms of IV thrombolysis, 80% (n = 6/8; all bar 23-212 and 23-254) received this treatment prior to thrombectomy; clearly it had little obvious effect on the overall clot properties. A specific separate proforma for recording the laboratory data and clot characteristics was used.

Initial macroscopic examination

Following 24hr formalin fixation, the specimen was examined macroscopically by the pathologists to include descriptors as outlined in the LNBW brain clot bank pathology report (not shown). A macrophotograph of each formalin fixed sample was obtained and stored in the archives.

Processing, initial staining and microscopic examination at the Walton Centre

A single, tubular fragment was embedded along the length of the thrombus. In case of fragmented specimens all the fragments were embedded in one block. The aim was to embed material so that a maximum cross-section is achieved when sectioning. Paraffin blocks were sectioned at a 3-5µm thickness. Paraffin blocks were trimmed until a full-face section of the clot is reached. Glass slides were labelled with the histology number. Although not reported here, all three levels of tissue sections were stained with Hematoxylin & Eosin (H&E), to assess the overall structure of the clot, and Martius Scarlet Blue (MSB) stains; the latter stain helps to differentiate fibrin from red blood cells (RBCs). Van Gieson staining was performed when required for assessment of collagen content.

ASPECTS were applied to capture the amount of the brain affected during the insult.

Sectioning, dewaxing and fluorescence microscopy at the University of Liverpool. Microtome sectioning and dewaxing was performed by cooling the clots' wax blocks on ice, followed by cutting 5 µm sections on a Leica RM2235 microtome. Sections were then de-waxed in xylene for 5 minutes, then hydrated in 100%, 90% and 70% ethanol, respectively. Each section was then transferred to individual wells in a 15-well glass bottom angiogenesis Ibidi slide (Grixti et al. 2024). Fluorescence microscopy using a Cytation 1 instrument and the fluorescent dye Thioflavin T was performed as described in (Grixti et al. 2024), following protocols developed by Dalton and colleagues (Dalton et al. 2024).

Results

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Clots were obtained from the clot bank held in Liverpool, UK, dewaxed as in Methods, exposed to thioflavin T (30 mM), and imaged in a Cytation-1 fluorescence microscope (Grixti et al. 2024). Figure 1 A-H shows slices from typical thrombectomies taken from each of the eight patients/ clots studied. From these striking pictures, it is evident that (i) there is in each case a massive amount of amyloid, shown by the green fluorescence of added thioflavin T, (ii) there is considerable heterogeneity in staining intensity within the clots, and (iii) there is considerable heterogeneity in staining between the clots. Adjacent to each of the micrographs is a histogram plot created using the histogram function in Image J. These show the distribution of pixel intensities for those samples. Again both these histograms and the images themselves show the very extensive heterogeneity of the clots as regards amyloid formation.

The substantial heterogeneity both within and between such clots has been observed by others (Dumitriu LaGrange et al. 2022; Liu et al. 2022). To quantify this more clearly, we show all the fluorescence intensity distributions of the eight images as distribution plots in Figure 2.

The chief point is that in every single case, regardless of the thrombus location or of other metadata given in Table 1, the extent of amyloid staining is truly massive, with in most cases the majority of the clot being amyloid in character. However, because of the relatively small numbers of clots studied, we do not perform further statistical analyses, and confine ourselves here to the headline message.

Table 1: Procedural Characteristics and Outcomes of Retrieved Thrombi. R elevant metadata for the wax-embedded clots extracted from the eight patients studied. The Thrombosis in Cerebral Infarction (TICI) scale (Higashida et al. 2003) is a tool used to grade the degree of perfusion obtained following recanalization of an arterial occlusion (0 meaning no perfusion). The ASPECTS (Alberta Stroke Program Early CT Score) (Mokin et al. 2017) is a quantitative score that measures the extent of early ischemic changes in anterior circulation hyperacute ischemic stroke.

Figure 1: Fluorescence images of 8 thrombectomies representing 8 samples from stroke patients. Samples were embedded in wax followed by sectioning, dewaxing and Thioflavin staining. Adjacent to each of the micrographs is a histogram plot showing the distribution of pixel intensities for each sample. The patients represented as A to H are given in Table 1.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Figure 2. Intensity distributions of the pixel values in the eight images given in Figure 1, illustrating the heterogeneity of staining both within and between samples.

While our chief interest here is the very extensive presence of amyloid in these microclots, as judged by the thioflavin T staining, it is of interest to get a feel for the extent of the amyloid distribution in different clots. To this end, using different slices, we also show in Figure 3 two paired brightfield and fluorescence images to illustrate the kind of heterogeneity observed. In one (patient 23-236; A, B) the amyloid is preferentially at the edges of the clot (plausibly explaining its resistance to fibrinolysis), while in the second example (patient 23-354; C, D) the amyloid is present more or less throughout the clot.

Figure 3: Paired amyloid-stained (A, C) and brightfield (B, D) images of two typical thrombectomised clots, as observed using the Cytation 1. Panels A and B are from Patient 23-236 (numerology as Table 1) while C and D are from patient 23-354.

Wax embedding is a very well-established medium for the detection of 'classical' amyloids using birefringent or fluorescent stains (Bély and Makovitzky 2006; Kung et al. 2002; Murphy et al. 2001; Shtrasburg et al. 1997; van de Kaa et al. 1986). Consequently, it is very implausible that these findings might simply be due to the wax embedding.

Discussion

Most analyses of retrieved thrombi have focused on morphology, specifically classifying thrombi as fibrin-rich or erythrocyte-rich to assist in imaging, procedural planning, and outcome prediction. Recently, studies have expanded to examine additional compositional elements, such as microbial signatures and inflammatory components, that may further influence thrombus morphology. It was observed more than ten years ago using the electron microscope that the clots observable following ischaemic stroke had an anomalous character, that was both denser and more matted than that of

normal clots (Pretorius et al. 2011a; Pretorius et al. 2011b; Pretorius et al. 2010). It was subsequently recognised that such 'dense matted deposits' (Pretorius et al. 2017a; Pretorius et al. 2013; Swanepoel et al. 2016) are in fact amyloid in nature (Pretorius et al. 2016; Pretorius et al. 2017b). What is clear from the present findings is that the clots extracted from stroke patients by mechanical thrombectomy are themselves considerably, and in some cases almost almost entirely, amyloid in character. This has considerable ramifications in terms of both the scientific understanding of their genesis and possible therapies. Molecules known to induce amyloid-type clotting include bacterial cell wall components (Pretorius et al. 2016; Pretorius et al. 2017b) and the SARS-CoV-2 spike protein (Grobbelaar et al. 2021), which is itself highly amyloidogenic (Larsson et al. 2023; Nyström and Hammarström 2022), and associated with stroke risk (Ab Rahman et al. 2024). It is thus pertinent that both kinds of infection are associated with an increased stroke risk (Westendorp et al. 2011; Zuin et al. 2023). Sepsis also increases both fibrinaloid formation (Schofield et al. 2024) and classical amyloidoses (Basak et al. 2021).

As well as the association of stroke with bacterial cell wall components, it is also of some considerable interest that clots may also in fact contain bacteria (Patrakka et al. 2021; Patrakka et al. 2019; Walker et al. 2022), since we have previously shown that even when present in minuscule concentrations bacterial cell wall products can catalyse the formation of fibrinaloid microclots (Pretorius et al. 2016; Pretorius et al. 2018b), and that oral bacteria are also associated with stoke (Aliena-Valero et al. 2021; Freiherr Von Seckendorff et al. 2024; Leonov et al. 2024; Staessens and De Meyer 2021; Yadav et al. 2023; Zhang et al. 2024a).

It is usually assumed that the clots underpinning the blockages in ischaemic stroke arrive at the sites where they act more or less fully formed (cerebral embolism) or by growing there 'in one event' (thrombosis). However, it seems implausible that these clots could all flip from a normal to an amyloid conformation after arriving at such sites, so one has to assume that – like other 'classical' amyloid fibrils – they formed by accretion, most plausibly for their amyloid portions from the pre-existing fibrinaloid microclots that have been widely observed in a variety of inflammatory diseases (e.g. (Dalton et al. 2024; Pretorius et al. 2018a; Pretorius and Kell 2024; Pretorius et al. 2017a; Pretorius et al. 2018c)), including Long COVID (Kell et al. 2022; Kell and Pretorius 2023, 2022; Pretorius et al. 2022; Turner et al. 2023b).

Although it is common to give recombinant tPA to stroke patients (Barreto 2011; Emberson et al. 2014) (6 of 8 in the present study received this treatment), it is evident visually (Figure 1) that this must have induced comparatively little macroscopic clot breakdown; those who did not receive tPA (Panels D and F in Fig 1) are not noticeably different in terms of amyloid staining from those that did (Figure 2). Given that tPA is the normal means of initiating fibrinolysis *in vivo* (before the stroke suffered by these individuals), and had evidently failed to break down the amyloid clots, it is possibly unsurprising that adding more had comparatively little effect.

The clots removed from ischaemic stroke patients by thrombectomy vary in size, and their lengths and diameters are correlated (Rossi et al. 2021), which is also consistent with the idea that they do grow by accretion. In that study (Rossi et al. 2021), typical clot lengths depended on the artery involved, were 12-20 mm long and of area 39-111 mm², equivalent to a circular diameter of ca 7-12 mm. Since typical clot fibril diameters are more like 100 nm (Pretorius et al. 2016) this implies further that they have been formed via the accretion of a great many fibres.

Other means of discriminating clot properties in terms of the outcomes following an ischaemic stroke include radiomics (Cahalane et al. 2021; Patel et al. 2023), transcriptomics (Santo et al. 2024) and proteomics (Desilles et al. 2022; Lopez-Pedrera et al. 2023); it will be of interest to see which elements of these may underlie the fibrinaloid phenotype. Penn *et al*. have sought proteomic biomarkers of stroke. Their first study of the clot proteome (Penn et al. 2018c) found proteins involved in inflammation (47%), coagulation (40%), and atrial fibrillation (7%), among others, atrial fibrillation being well associated with stroke risk (Kell et al. 2024), as well as a prothrombotic state (Bartus et al. 2020; Glowicki et al. 2019; Mołek et al. 2022). Their later studies (SpecTRA (Penn et

al. 2018a; Penn et al. 2018b)) included thrombospondin and VWF as part of a biomarker panel. Validation studies showed that both thrombospondin and apolipoprotein B contributed; both had been seen as amyloidogenic markers in fibrinaloid microclots (Kell and Pretorius 2024), with thrombospondin – despite its modest concentration in both plasma (Buda et al. 2019; Kalaidopoulou Nteak et al. 2024) and in normal clots (Ząbczyk et al. 2019) – having the potential to be incorporated into the fibrin strands themselves (Bale 1987; Bale and Mosher 1986a, b; Bale et al. 1985)

Staessens *et al*. (Staessens et al. 2021a; Staessens et al. 2021b) and others (Kitano et al. 2022) also found neutrophil extracellular traps (NETs) in the thrombus taken from ischaemic strokes, where they were related to the severity (Denorme et al. 2022); NETs are also an important feature of fibrinaloid microclots (Pretorius et al. 2024), and were found in prothrombotic clots in the studies of Ząbczyk *et al*. (Ząbczyk et al. 2020). In particular, lower levels of extracellular DNA were related to the ease of thrombectomy (Vandelanotte et al. 2024).

Note that we are here focused on standard ischaemic stroke, though we recognise the existence of cerebral amyloid angiopathy (Jäkel et al. 2022; Theodorou et al. 2023), which is a type of cerebrovascular disorder that is indeed known to be characterized by the accumulation of amyloid beta-peptide within cerebral blood vessels.

Although this was a small sample, it is clear, as is recognised by other methods (Boodt et al. 2021; Goebel et al. 2020; Huang et al. 2022; Huang and Bhaskar 2022; Jolugbo and Ariëns 2021; Staessens and De Meyer 2021; Zhang et al. 2024b), that the clots are themselves highly heterogeneous, both within and between samples.

The recanalization rates of intravenous thrombolytics range between 30-60% in the first 6-24 hours, though the reasons for such poor rates are not entirely known (Molina et al. 2001). Here the clots remained as amyloid in nature despite the application of recombinant tPA ('alteplase') in 6 of the 8 patients. Despite the effectiveness of thrombectomy, futile recanalization, in which patients achieve successful recanalization but fail to improve their functional outcome, is surprisingly common, and a variety of risk factors are known (Deng et al. 2023; Deng et al. 2022; Karimian-Jazi et al. 2024; Nie et al. 2018; Nogueira et al. 2024; Shen et al. 2023; Zhou et al. 2022). A biochemical marker that might be predictive of futile recanalization would be of significant value, and it is not unreasonable that fibrinaloid microclots might provide one, just as they have in sepsis (Schofield et al. 2024). Future studies will seek to address this.

Acknowledgments. We thank Drs Nitika Rathi and Piyali Pal for basic analyses of the clots, Mr Khaja Syed for setting up the clot bank and facilitating the transfer of material to Liverpool University, Ms Sally Flintham for help with clot collection and transfer, Ms Helen Malone for assistance including the consenting, and Ms Marie O'Brien for skilled assistance with microtoming and dewaxing at the University of Liverpool.

Supplementary Materials. None.

Author Contributions. AC performed the thrombectomies. JMG performed the fluorescence microscopy. JHP contributed the statistical analysis of the images. DBK, EP, AS and MW contributed to the conceptualisation, analyses, funding acquisition, drafting, and final editing. All authors contributed to the drafting and final editing, and have read and agreed to the published version of the manuscript.

Funding. DBK thanks the Balvi Foundation (grant 18) and the Novo Nordisk Foundation for funding (grant NNF20CC0035580). EP: Funding was provided by NRF of South Africa (grant number 142142), SA MRC (self-initiated research (SIR) grant), and the Balvi Foundation. The content and findings reported and illustrated are the sole deduction, view, and responsibility of the researchers and do not reflect the official position and sentiments of the funders.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Data Availability Statement. All relevant data are provided.

Conflicts of Interest. EP is a named inventor on a patent application covering the use of fluorescence methods for microclot detection in long COVID. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Other authors have no conflicts.

References

Ab Rahman N, King TL, Peariasamy KM, Sivasampu S, SAFECOVAC study group: Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study. *Vaccine* 2024; 42:126465.

Al-Ajlan FS, Alkhiri A, Alamri AF, Alghamdi BA, Almaghrabi AA, Alharbi AR, Alansari N, Almilibari AZ, Hussain MS, Audebert HJ, Grotta JC, Shuaib A, Saver JL, Alhazzani A: Golden Hour Intravenous Thrombolysis for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. *Ann Neurol* 2024. Aliena-Valero A, Baixauli-Martin J, Torregrosa G, Tembl JI, Salom JB: Clot Composition Analysis as a Diagnostic Tool to Gain Insight into Ischemic Stroke Etiology: A Systematic Review. *J Stroke* 2021; 23:327-342.

Amdursky N, Erez Y, Huppert D: Molecular rotors: what lies behind the high sensitivity of the thioflavin-T fluorescent marker. *Acc Chem Res* 2012; 45:1548-1557.

Bale MD: Noncovalent and covalent interactions of thrombospondin with polymerizing fibrin. *Semin Thromb Hemost* 1987; 13:326-334.

Bale MD, Mosher DF: Effects of thrombospondin on fibrin polymerization and structure. *J Biol Chem* 1986a; 261:862-868.

Bale MD, Mosher DF: Thrombospondin is a substrate for blood coagulation factor XIIIa. *Biochemistry* 1986b; 25:5667-5673.

Bale MD, Westrick LG, Mosher DF: Incorporation of thrombospondin into fibrin clots. *J Biol Chem* 1985; 260:7502-7508.

Barreto AD: Intravenous thrombolytics for ischemic stroke. *Neurotherapeutics* 2011; 8:388-399.

Bartus K, Litwinowicz R, Natorska J, Zabczyk M, Undas A, Kapelak B, Lakkireddy D, Lee RJ: Coagulation factors and fibrinolytic activity in the left atrial appendage and other heart chambers in patients with atrial fibrillation: is there a local intracardiac prothrombotic state? (HEART-CLOT study). *Int J Cardiol* 2020; 301:103-107.

Basak JM, Ferreiro A, Cohen LS, Sheehan PW, Nadarajah CJ, Kanan MF, Sukhum KV, Dantas G, Musiek ES: Bacterial sepsis increases hippocampal fibrillar amyloid plaque load and neuroinflammation in a mouse model of Alzheimer's disease. *Neurobiol Dis* 2021; 152:105292.

Bély M, Makovitzky J: Sensitivity and specificity of Congo red staining according to Romhányi. Comparison with Puchtler's or Bennhold's methods. *Acta Histochem* 2006; 108:175-180.

Bergaglio T, Synhaivska O, Nirmalraj PN: 3D Holo-tomographic Mapping of COVID-19 Microclots in Blood to Assess Disease Severity. *ACS Chem Biomed Imaging* 2024:online.

Biancalana M, Koide S: Molecular mechanism of Thioflavin-T binding to amyloid fibrils. *Biochim Biophys Acta* 2010; 1804:1405-1412.

Boodt N, Snouckaert van Schauburg PRW, Hund HM, Fereidoonnezhad B, McGarry JP, Akyildiz AC, van Es A, De Meyer SF, Dippel DWJ, Lingsma HF, van Beusekom HMM, van der Lugt A, Gijsen FJH: Mechanical Characterization of Thrombi Retrieved With Endovascular Thrombectomy in Patients With Acute Ischemic Stroke. *Stroke* 2021; 52:2510-2517.

Buda V, Andor M, Cristescu C, Tomescu MC, Muntean DM, Baibata DE, Bordejevic DA, Danciu C, Dalleur O, Coricovac D, Crainiceanu Z, Tudor A, Ledeti I, Petrescu L: Thrombospondin-1 Serum Levels In Hypertensive Patients With Endothelial Dysfunction After One Year Of Treatment With Perindopril. *Drug Des Devel Ther* 2019; 13:3515-3526.

Cahalane R, Boodt N, Akyildiz AC, Giezen JA, Mondeel M, van der Lugt A, Marquering H, Gijsen F: A review on the association of thrombus composition with mechanical and radiological imaging characteristics in acute ischemic stroke. *J Biomech* 2021; 129:110816.

Campbell BCV, Majoie C, Albers GW, Menon BK, Yassi N, Sharma G, van Zwam WH, van Oostenbrugge RJ, Demchuk AM, Guillemin F, White P, Davalos A, van der Lugt A, Butcher KS, Cherifi A, Marquering HA, Cloud G, Macho Fernandez JM, Madigan J, Oppenheim C, Donnan GA, Roos Y, Shankar J, Lingsma H, Bonafe A, Raoult H, Hernández-Pérez M, Bharatha A, Jahan R, Jansen O, Richard S, Levy EI, Berkhemer OA, Soudant M, Aja L, Davis SM, Krings T, Tisserand M, San Roman L, Tomasello A, Beumer D, Brown S, Liebeskind DS, Bracard S, Muir KW, Dippel DWJ, Goyal M, Saver JL, Jovin TG, Hill MD, Mitchell PJ, HERMES collaborators: Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data. *Lancet Neurol* 2019; 18:46-55.

Chisholm TS, Hunter CA: A closer look at amyloid ligands, and what they tell us about protein aggregates. *Chem Soc Rev* 2024; 53:1354-1374.

Dalton CF, de Oliveira MIR, Stafford P, Peake N, Kane B, Higham A, Singh D, Jackson N, Davies H, Price D, Duncan R, Tattersall N, Barnes A, Smith DP: Increased fibrinaloid microclot counts in platelet-poor plasma are associated with Long COVID. *medRxiv* 2024:2024.2004.2004.24305318.

Deng G, Chu YH, Xiao J, Shang K, Zhou LQ, Qin C, Tian DS: Risk Factors, Pathophysiologic Mechanisms, and Potential Treatment Strategies of Futile Recanalization after Endovascular Therapy in Acute Ischemic Stroke. *Aging Dis* 2023; 14:2096-2112.

Deng G, Xiao J, Yu H, Chen M, Shang K, Qin C, Tian DS: Predictors of futile recanalization after endovascular treatment in acute ischemic stroke: a meta-analysis. *J Neurointerv Surg* 2022; 14:881- 885.

Denorme F, Portier I, Rustad JL, Cody MJ, de Araujo CV, Hoki C, Alexander MD, Grandhi R, Dyer MR, Neal MD, Majersik JJ, Yost CC, Campbell RA: Neutrophil extracellular traps regulate ischemic stroke brain injury. *J Clin Invest* 2022; 132.

Desilles JP, Di Meglio L, Delvoye F, Maïer B, Piotin M, Ho-Tin-Noé B, Mazighi M: Composition and Organization of Acute Ischemic Stroke Thrombus: A Wealth of Information for Future Thrombolytic Strategies. *Front Neurol* 2022; 13:870331.

Donkor ES: Stroke in the 21(st) Century: A Snapshot of the Burden, Epidemiology, and Quality of Life. *Stroke Res Treat* 2018; 2018:3238165.

Dumitriu LaGrange D, Braunersreuther V, Wanke I, Berberat J, Luthman S, Fitzgerald S, Doyle KM, Brina O, Reymond P, Platon A, Muster M, Machi P, Poletti PA, Vargas MI, Lövblad KO: MicroCT Can Characterize Clots Retrieved With Mechanical Thrombectomy From Acute Ischemic Stroke Patients-A Preliminary Report. *Front Neurol* 2022; 13:824091.

El Tawil S, Muir KW: Thrombolysis and thrombectomy for acute ischaemic stroke. *Clin Med (Lond)* 2017; 17:161-165.

Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, del Zoppo GJ, Baigent C, Sandercock P, Hacke W, Stroke Thrombolysis Trialists' Collaborative G: Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. *Lancet* 2014; 384:1929-1935.

Freiherr Von Seckendorff A, Nomenjanahary MS, Labreuche J, Ollivier V, Di Meglio L, Dupont S, Hamdani M, Brikci-Nigassa N, Brun A, Boursin P, Piotin M, Mazighi M, Ho-Tin-Noe B, Desilles JP, Delbosc S, compoCLOT study group: Periodontitis in ischemic stroke: impact of Porphyromonas gingivalis on thrombus composition and ischemic stroke outcomes. *Res Pract Thromb Haemost* 2024; 8:102313.

GBD 2019 Stroke Collaborators: Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Neurol* 2021; 20:795-820.

Glowicki B, Matusik PT, Plens K, Undas A: Prothrombotic State in Atrial Fibrillation Patients With One Additional Risk Factor of the CHA(2)DS(2)-VASc Score (Beyond Sex). *Can J Cardiol* 2019; 35:634-643.

Goebel J, Gaida BJ, Wanke I, Kleinschnitz C, Koehrmann M, Forsting M, Moenninghoff C, Radbruch A, Junker A: Is Histologic Thrombus Composition in Acute Stroke Linked to Stroke Etiology or to Interventional Parameters? *AJNR Am J Neuroradiol* 2020; 41:650-657.

Grixti JM, Theron CW, Salcedo-Sora JE, Pretorius E, Kell DB: Automated microscopic measurement of fibrinaloid microclots and their degradation by nattokinase, the main natto protease. *bioRxiv* 2024:2024.2004.2006.588397.

Grobbelaar LM, Kruger A, Venter C, Burger EM, Laubscher GJ, Maponga TG, Kotze MJ, Kwaan HC, Miller JB, Fulkerson D, Huff W, Chang E, Wiarda G, Bunch CM, Walsh MM, Raza S, Zamlut M, Moore HB, Moore EE, Neal MD, Kell DB, Pretorius E: Relative hypercoagulopathy of the SARS-CoV-2 Beta and Delta variants when compared to the less severe Omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. *Semin Thromb Haemost* 2022; 48:858-868.

Grobbelaar LM, Venter C, Vlok M, Ngoepe M, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Pretorius E: SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. *Biosci Rep* 2021; 41:BSR20210611.

Gurman P, Miranda OR, Nathan A, Washington C, Rosen Y, Elman NM: Recombinant tissue plasminogen activators (rtPA): a review. *Clin Pharmacol Ther* 2015; 97:274-285.

Hammed A, Al-Qiami A, Alzawahreh A, Rosenbauer J, Ayman Nada E, Otmani Z, N GH, Zakria Alnajjar A, Mohamed Hammad E, Hamamreh R, Kostev K, Richter G, Tanislav C: Comparative Effectiveness of Intravenous Thrombolysis plus Mechanical Thrombectomy versus Mechanical Thrombectomy Alone in Acute Ischaemic Stroke: A systematic review and Meta-Analysis. *Cerebrovasc Dis* 2024.

He Q, Wang W, Zhang Y, Xiong Y, Tao C, Ma L, Ma J, You C, Wang C: Global, Regional, and National Burden of Stroke, 1990-2021: A Systematic Analysis for Global Burden of Disease 2021. *Stroke* 2024.

Heiferman DM, Li DD, Pecoraro NC, Smolenski AM, Tsimpas A, Ashley WW, Jr.: Intra-Arterial Alteplase Thrombolysis during Mechanical Thrombectomy for Acute Ischemic Stroke. *J Stroke Cerebrovasc Dis* 2017; 26:3004-3008.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D, Technology Assessment Committee of the American Society of I, Therapeutic N, Technology Assessment Committee of the Society of Interventional R: Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. *Stroke* 2003; 34:e109- 137.

Ho-Tin-Noé B, Desilles JP, Mazighi M: Thrombus composition and thrombolysis resistance in stroke. *Res Pract Thromb Haemost* 2023; 7:100178.

Huang J, Killingsworth MC, Bhaskar SMM: Is Composition of Brain Clot Retrieved by Mechanical Thrombectomy Associated with Stroke Aetiology and Clinical Outcomes in Acute Ischemic Stroke?- A Systematic Review and Meta-Analysis. *Neurol Int* 2022; 14:748-770.

Huang JC, Bhaskar SMM: Clot Morphology in Acute Ischemic Stroke Decision Making. *Int J Mol Sci* 2022; 23:12373.

Hurford R, Sekhar A, Hughes TAT, Muir KW: Diagnosis and management of acute ischaemic stroke. *Pract Neurol* 2020; 20:304-316.

Jäkel L, De Kort AM, Klijn CJM, Schreuder FHBM, Verbeek MM: Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. *Alzheimers Dement* 2022; 18:10-28.

Jolugbo P, Ariëns RAS: Thrombus Composition and Efficacy of Thrombolysis and Thrombectomy in Acute Ischemic Stroke. *Stroke* 2021; 52:1131-1142.

Kalaidopoulou Nteak S, Völlmy F, Lukassen MV, van den Toorn H, den Boer MA, Bondt A, van der Lans SPA, Haas PJ, van Zuilen AD, Rooijakkers SHM, Heck AJR: Longitudinal Fluctuations in Protein Concentrations and Higher-Order Structures in the Plasma Proteome of Kidney Failure Patients Subjected to a Kidney Transplant. *J Proteome Res* 2024; 23:2124-2136.

Karimian-Jazi K, Vollherbst DF, Schwarz D, Fischer M, Schregel K, Bauer G, Kocharyan A, Sturm V, Neuberger U, Jesser J, Herweh C, Ulfert C, Hilgenfeld T, Seker F, Preisner F, Schmitt N, Charlet T, Hamelmann S, Sahm F, Heiland S, Wick W, Ringleb PA, Schirmer L, Bendszus M, Möhlenbruch MA, Breckwoldt MO: MR microscopy to assess clot composition following mechanical thrombectomy predicts recanalization and clinical outcome. *J Neurointerv Surg* 2024; 16:830-837.

Kell DB, Laubscher GJ, Pretorius E: A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. *Biochem J* 2022; 479:537-559.

Kell DB, Lip GYH, Pretorius E: Fibrinaloid Microclots and Atrial Fibrillation. *Biomedicines* 2024; 12:891.

Kell DB, Pretorius E: Are fibrinaloid microclots a cause of autoimmunity in Long Covid and other post-infection diseases? *Biochem J* 2023; 480:1217-1240.

Kell DB, Pretorius E: The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, long COVID and ME/CFS: evidence, mechanisms, and therapeutic implications. *Biochem J* 2022; 479:1653-1708.

Kell DB, Pretorius E: Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. *Progr Biophys Mol Biol* 2017; 123:16-41.

Kell DB, Pretorius E: Proteomic evidence for amyloidogenic cross-seeding in fibrinaloid microclots. *Int J Mol Sci* 2024; 25:10809.

Kitano T, Hori Y, Okazaki S, Shimada Y, Iwamoto T, Kanki H, Sugiyama S, Sasaki T, Nakamura H, Oyama N, Hoshi T, Beck G, Takai H, Matsubara S, Mizuno H, Nishimura H, Tamaki R, Iida J, Iba J, Uno M, Kishima H, Fushimi H, Hattori S, Murayama S, Morii E, Sakaguchi M, Yagita Y, Shimazu T, Mochizuki H, Todo K: An Older Thrombus Delays Reperfusion after Mechanical Thrombectomy for Ischemic Stroke. *Thromb Haemost* 2022; 122:415-426.

Kruger A, Vlok M, Turner S, Venter C, Laubscher GJ, Kell DB, Pretorius E: Proteomics of fibrin amyloid microclots in Long COVID/ Post-Acute Sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. *Cardiovasc Diabetol* 2022; 21:190.

Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ, Lee VM, Kung HF: IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. *Brain Res* 2002; 956:202-210.

Larsson J, Hellstrand E, Hammarström P, Nyström S: SARS-CoV-2 Spike amyloid fibrils specifically and selectively accelerates amyloid fibril formation of human prion protein and the amyloid β peptide. *bioRxiv* 2023:2023.2009.2001.555834.

Leonov G, Salikhova D, Starodubova A, Vasilyev A, Makhnach O, Fatkhudinov T, Goldshtein D: Oral Microbiome Dysbiosis as a Risk Factor for Stroke: A Comprehensive Review. *Microorganisms* 2024; 12:1732.

Liu Y, Brinjikji W, Abbasi M, Dai D, Arturo Larco JL, Madhani SI, Shahid AH, Mereuta OM, Nogueira RG, Kvamme P, Layton KF, Delgado Almandoz JE, Hanel RA, Mendes Pereira V, Almekhlafi MA, Yoo AJ, Jahromi BS, Gounis MJ, Patel B, Fitzgerald S, Doyle K, Haussen DC, Al-Bayati AR, Mohammaden M, Pisani L, Rodrigues GM, Thacker IC, Kayan Y, Copelan A, Aghaebrahim A, Sauvageau E, Demchuk AM, Bhuva P, Soomro J, Nazari P, Cantrell DR, Puri AS, Entwistle J, Kadirvel R, Cloft HJ, Kallmes DF, Savastano L: Quantification of clot spatial heterogeneity and its impact on thrombectomy. *J Neurointerv Surg* 2022; 14:1248-1252.

Lopez-Pedrera C, Oteros R, Ibáñez-Costa A, Luque-Tévar M, Muñoz-Barrera L, Barbarroja N, Chicano-Gálvez E, Marta-Enguita J, Orbe J, Velasco F, Perez-Sanchez C: The thrombus proteome in stroke reveals a key role of the innate immune system and new insights associated with its etiology, severity, and prognosis. *J Thromb Haemost* 2023; 21:2894-2907.

Martha SR, Levy SH, Federico E, Levitt MR, Walker M: Machine Learning Analysis of the Cerebrovascular Thrombi Lipidome in Acute Ischemic Stroke. *J Neurosci Nurs* 2023; 55:10-17.

Martin-Gutiérrez A, Leal-Vega L, Coco-Martin MB, Arenillas-Lara JF: A systematic review of the socioeconomic impact of mechanical thrombectomy for acute ischemic stroke. *J Stroke Cerebrovasc Dis* 2024:107906.

Menon BK, Hill MD, Davalos A, Roos Y, Campbell BCV, Dippel DWJ, Guillemin F, Saver JL, van der Lugt A, Demchuk AM, Muir K, Brown S, Jovin T, Mitchell P, White P, Bracard S, Goyal M: Efficacy of endovascular thrombectomy in patients with M2 segment middle cerebral artery occlusions: metaanalysis of data from the HERMES Collaboration. *J Neurointerv Surg* 2019; 11:1065-1069.

Mokin M, Primiani CT, Siddiqui AH, Turk AS: ASPECTS (Alberta Stroke Program Early CT Score) Measurement Using Hounsfield Unit Values When Selecting Patients for Stroke Thrombectomy. *Stroke* 2017; 48:1574-1579.

Mołek P, Ząbczyk M, Malinowski KP, Natorska J, Undas A: Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state. *Thromb Res* 2022; 213:1-7. Molina CA, Montaner J, Abilleira S, Arenillas JF, Ribo M, Huertas R, Romero F, Alvarez-Sabin J: Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. *Stroke* 2001; 32:2821-2827.

Murphy CL, Eulitz M, Hrncic R, Sletten K, Westermark P, Williams T, Macy SD, Wooliver C, Wall J, Weiss DT, Solomon A: Chemical typing of amyloid protein contained in formalin-fixed paraffinembedded biopsy specimens. *Am J Clin Pathol* 2001; 116:135-142.

Nie X, Pu Y, Zhang Z, Liu X, Duan W, Liu L: Futile Recanalization after Endovascular Therapy in Acute Ischemic Stroke. *Biomed Res Int* 2018; 2018:5879548.

Nogueira RG, Pinheiro A, Brinjikji W, Abbasi M, Al-Bayati AR, Mohammaden MH, Souza Viana L, Ferreira F, Abdelhamid H, Bhatt NR, Kvamme P, Layton KF, Delgado Almandoz JE, Hanel RA, Mendes Pereira V, Almekhlafi MA, Yoo AJ, Jahromi BS, Gounis MJ, Patel B, Arturo Larco JL, Fitzgerald S, Mereuta OM, Doyle K, Savastano LE, Cloft HJ, Thacker IC, Kayan Y, Copelan A, Aghaebrahim A, Sauvageau E, Demchuk AM, Bhuva P, Soomro J, Nazari P, Cantrell DR, Puri AS, Entwistle J, Polley EC, Frankel MR, Kallmes DF, Haussen DC: Clot composition and recanalization outcomes in mechanical thrombectomy. *J Neurointerv Surg* 2024; 16:466-470.

Nunes JM, Kruger A, Proal A, Kell DB, Pretorius E: The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). *Pharmaceuticals (Basel)* 2022; 15:931.

Nyström S, Hammarström P: Amyloidogenesis of SARS-CoV-2 Spike Protein. *J Am Chem Soc* 2022; 144:8945-8950.

Patel TR, Santo BA, Baig AA, Waqas M, Monterio A, Levy EI, Siddiqui AH, Tutino VM: Histologically interpretable clot radiomic features predict treatment outcomes of mechanical thrombectomy for ischemic stroke. *Neuroradiology* 2023; 65:737-749.

Patrakka O, Mehtonen H, Tuomisto S, Pienimäki JP, Ollikainen J, Huhtala H, Pessi T, Oksala N, Lehtimäki T, Järnstedt J, Martiskainen M, Karhunen PJ: Association between Oral Pathology, Carotid Stenosis, and Oral Bacterial DNA in Cerebral Thrombi of Patients with Stroke. *Stroke Res Treat* 2021; 2021:5402764.

Patrakka O, Pienimäki JP, Tuomisto S, Ollikainen J, Lehtimäki T, Karhunen PJ, Martiskainen M: Oral Bacterial Signatures in Cerebral Thrombi of Patients With Acute Ischemic Stroke Treated With Thrombectomy. *J Am Heart Assoc* 2019; 8:e012330.

Penn AM, Bibok MB, Saly VK, Coutts SB, Lesperance ML, Balshaw RF, Votova K, Croteau NS, Trivedi A, Jackson AM, Hegedus J, Klourfeld E, Yu AYX, Zerna C, Borchers CH, SpecTRA study group: Verification of a proteomic biomarker panel to diagnose minor stroke and transient ischaemic attack: phase 1 of SpecTRA, a large scale translational study. *Biomarkers* 2018a; 23:392-405.

Penn AM, Bibok MB, Saly VK, Coutts SB, Lesperance ML, Balshaw RF, Votova K, Croteau NS, Trivedi A, Jackson AM, Hegedus J, Klourfeld E, Yu AYX, Zerna C, Modi J, Barber PA, Hoag G, Borchers CH, SpecTRA study group: Validation of a proteomic biomarker panel to diagnose minorstroke and transient ischaemic attack: phase 2 of SpecTRA, a large scale translational study. *Biomarkers* 2018b; 23:793-803.

Penn AM, Saly V, Trivedi A, Lesperance ML, Votova K, Jackson AM, Croteau NS, Balshaw RF, Bibok MB, Smith DS, Lam KK, Morrison J, Lu L, Coutts SB, Borchers CH: Differential Proteomics for Distinguishing Ischemic Stroke from Controls: a Pilot Study of the SpecTRA Project. *Transl Stroke Res* 2018c; 9:590-599.

Powers WJ: Acute Ischemic Stroke. *N Engl J Med* 2020; 383:252-260.

Pretorius E, Bester J, Page MJ, Kell DB: The potential of LPS-binding protein to reverse amyloid formation in plasma fibrin of individuals with Alzheimer-type dementia. *Frontiers Aging Neurosci* 2018a; 10:257.

Pretorius E, Kell DB: A Perspective on How Fibrinaloid Microclots and Platelet Pathology May be Applied in Clinical Investigations. *Semin Thromb Hemost* 2024; 50:537-551.

Pretorius E, Mbotwe S, Bester J, Robinson CJ, Kell DB: Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide. *J R Soc Interface* 2016; 123:20160539.

Pretorius E, Page MJ, Engelbrecht L, Ellis GC, Kell DB: Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains. *Cardiovasc Diabetol* 2017a; 16:141.

Pretorius E, Page MJ, Hendricks L, Nkosi NB, Benson SR, Kell DB: Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: assessment with novel Amytracker™ stains. *J R Soc Interface* 2018b; 15:20170941.

Pretorius E, Page MJ, Hendricks L, Nkosi NB, Benson SR, Kell DB: Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: assessment with novel Amytracker™ stains. bioRxiv preprint. *bioRxiv* 2017b:143867.

Pretorius E, Page MJ, Mbotwe S, Kell DB: Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease. *PlosOne* 2018c; 13:e0192121.

Pretorius E, Steyn H, Engelbrecht M, Swanepoel AC, Oberholzer HM: Differences in fibrin fiber diameters in healthy individuals and thromboembolic ischemic stroke patients. *Blood Coagul Fibrinolysis* 2011a; 22:696-700.

Pretorius E, Swanepoel AC, Oberholzer HM, van der Spuy WJ, Duim W, Wessels PF: A descriptive investigation of the ultrastructure of fibrin networks in thrombo-embolic ischemic stroke. *J Thromb Thrombolysis* 2011b; 31:507-513.

Pretorius E, Thierry A, Sanchez C, Ha T, Pastor B, Mirandola A, Pisareva E, Prevostel C, Laubscher G, Usher T, Venter C, Turner S, Waters M, Kell DB: Circulating microclots are structurally associatedwith Neutrophil Extracellular Traps and theiramounts are strongly elevated in long COVID patients. *Res Square* 2024[:https://www.researchsquare.com/article/rs-4666650/v4666651.](https://www.researchsquare.com/article/rs-4666650/v4666651)

Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo S, Watson LR, Rajaratnam K, Watson BW, Kell DB: Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/ Post-Acute Sequelae of COVID-19 (PASC) *Cardiovasc Diabetol* 2022; 21:148.

Pretorius E, Vermeulen N, Bester J, Lipinski B, Kell DB: A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: the use of scanning electron microscopy. *Toxicol Mech Methods* 2013; 23:352-359.

Pretorius E, Windberger UB, Oberholzer HM, Auer RE: Comparative ultrastructure of fibrin networks of a dog after thrombotic ischaemic stroke. *Onderstepoort J Vet Res* 2010; 77:E1-4.

Rossi R, Fitzgerald S, Gil SM, Mereuta OM, Douglas A, Pandit A, Brennan P, Power S, Alderson J, O'Hare A, Gilvarry M, McCarthy R, Psychogios K, Magoufis G, Tsivgoulis G, Szikora I, Jood K, Redfors P, Nordanstig A, Ceder E, Tatlisumak T, Rentzos A, Thornton J, Doyle KM: Correlation between acute ischaemic stroke clot length before mechanical thrombectomy and extracted clot area: Impact of thrombus size on number of passes for clot removal and final recanalization. *Eur Stroke J* 2021; 6:254-261.

Rossi R, Molina S, Mereuta OM, Douglas A, Fitzgerald S, Tierney C, Pandit A, Brennan P, Power S, O'Hare A, Gilvarry M, McCarthy R, Magoufis G, Tsivgoulis G, Nagy A, Vadász A, Jood K, Redfors P, Nordanstig A, Ceder E, Dunker D, Carlqvist J, Psychogios K, Szikora I, Tatlisumak T, Rentzos A, Thornton J, Doyle KM: Does prior administration of rtPA influence acute ischemic stroke clot composition? Findings from the analysis of clots retrieved with mechanical thrombectomy from the RESTORE registry. *J Neurol* 2022; 269:1913-1920.

Röther J, Ford GA, Thijs VN: Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities. *Cerebrovasc Dis* 2013; 35:313-319.

Santo BA, Poppenberg KE, Ciecierska SS, Lim J, Baig AA, Jaikumar V, Raygor KP, Patel TR, Shah M, Levy EI, Siddiqui AH, Tutino VM: Decoding Molecular Mechanisms Underlying Outcomes After Ischemic Stroke Thrombectomy by RNA Sequencing of Retrieved Clots. *Mol Diagn Ther* 2024; 28:469-477.

Schofield J, Abrams ST, Jenkins R, Lane S, Wang G, Toh CH: Amyloid-fibrinogen aggregates ("microclots") predict risks of Disseminated Intravascular Coagulation and mortality. *Blood Adv* 2024; 8:2499-2508.

Shen H, Killingsworth MC, Bhaskar SMM: Comprehensive Meta-Analysis of Futile Recanalization in Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy: Prevalence, Factors, and Clinical Outcomes. *Life (Basel)* 2023; 13.

Shtrasburg S, Livneh A, Pras M, Weinstein T, Gal R: Detection of serum amyloid A-derived proteins in formalin-fixed paraffin-embedded tissues: reliability of the method and expansion of its spectrum. *Am J Clin Pathol* 1997; 108:289-294.

Staessens S, De Meyer SF: Thrombus heterogeneity in ischemic stroke. *Platelets* 2021; 32:331-339. Staessens S, Francois O, Brinjikji W, Doyle KM, Vanacker P, Andersson T, De Meyer SF: Studying Stroke Thrombus Composition After Thrombectomy: What Can We Learn? *Stroke* 2021a; 52:3718- 3727.

Staessens S, Francois O, Desender L, Vanacker P, Dewaele T, Sciot R, Vanhoorelbeke K, Andersson T, De Meyer SF: Detailed histological analysis of a thrombectomy-resistant ischemic stroke thrombus: a case report. *Thromb J* 2021b; 19:11.

Suzuki K, Matsumaru Y, Takeuchi M, Morimoto M, Kanazawa R, Takayama Y, Kamiya Y, Shigeta K, Okubo S, Hayakawa M, Ishii N, Koguchi Y, Takigawa T, Inoue M, Naito H, Ota T, Hirano T, Kato N,

Ueda T, Iguchi Y, Akaji K, Tsuruta W, Miki K, Fujimoto S, Higashida T, Iwasaki M, Aoki J, Nishiyama Y, Otsuka T, Kimura K, Investigators SS: Effect of Mechanical Thrombectomy Without vs With Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke: The SKIP Randomized Clinical Trial. *JAMA* 2021; 325:244-253.

Swanepoel AC, Visagie A, de Lange Z, Emmerson O, Nielsen VG, Pretorius E: The clinical relevance of altered fibrinogen packaging in the presence of 17beta-estradiol and progesterone. *Thromb Res* 2016; 146:23-34.

Theodorou A, Palaiodimou L, Malhotra K, Zompola C, Katsanos AH, Shoamanesh A, Boviatsis E, Dardiotis E, Spilioti M, Sacco S, Werring DJ, Cordonnier C, Alexandrov AV, Paraskevas GP, Tsivgoulis G: Clinical, Neuroimaging, and Genetic Markers in Cerebral Amyloid Angiopathy-Related Inflammation: A Systematic Review and Meta-Analysis. *Stroke* 2023; 54:178-188.

Turner S, Khan MA, Putrino D, Woodcock A, Kell DB, Pretorius E: Long COVID: pathophysiological factors and abnormal coagulation. *Trends Endocrinol Metab* 2023a; 34:321-344.

Turner S, Laubscher GJ, Khan MA, Kell DB, Pretorius E: Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model *Heliyon* 2023b; 9:e19605.

van de Kaa CA, Hol PR, Huber J, Linke RP, Kooiker CJ, Gruys E: Diagnosis of the type of amyloid in paraffin wax embedded tissue sections using antisera against human and animal amyloid proteins. *Virchows Arch A Pathol Anat Histopathol* 1986; 408:649-664.

Vandelanotte S, Staessens S, Francois O, De Wilde M, Desender L, De Sloovere AS, Dewaele T, Tersteeg C, Vanhoorelbeke K, Vanacker P, Andersson T, De Meyer SF: Association between thrombus composition and first-pass recanalization after thrombectomy in acute ischemic stroke. *J Thromb Haemost* 2024.

Walker M, Uranga C, Levy SH, Kelly C, Edlund A: Thrombus-associated microbiota in acute ischemic stroke patients. *Surg Neurol Int* 2022; 13:247.

Wardlaw JM, Murray V, Berge E, del Zoppo GJ: Thrombolysis for acute ischaemic stroke. *Cochrane Database Syst Rev* 2014; 2014:CD000213.

Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D: Post-stroke infection: a systematic review and meta-analysis. *BMC Neurol* 2011; 11:110.

Wilson JT, Hareendran A, Hendry A, Potter J, Bone I, Muir KW: Reliability of the modified Rankin Scale across multiple raters: benefits of a structured interview. *Stroke* 2005; 36:777-781.

Yadav LB, Tiwari S, Vajpeyee M, Vajpeyee A: Microbial Signature Present in Thrombotic Material of Acute Ischemic Stroke Patients Retrieved by Mechanical Thrombectomy. *Clin Neurochem* 2023; 17:482-491.

Ząbczyk M, Natorska J, Janion-Sadowska A, Metzgier-Gumiela A, Polak M, Plens K, Janion M, Skonieczny G, Mizia-Stec K, Undas A: Prothrombotic fibrin clot properties associated with NETs formation characterize acute pulmonary embolism patients with higher mortality risk. *Sci Rep* 2020; 10:11433.

Ząbczyk M, Stachowicz A, Natorska J, Olszanecki R, Wiśniewski JR, Undas A: Plasma fibrin clot proteomics in healthy subjects: Relation to clot permeability and lysis time. *J Proteomics* 2019; 208:103487.

Zhang W, Tang R, Yin Y, Chen J, Yao L, Liu B: Microbiome signatures in ischemic stroke: A systematic review. *Heliyon* 2024a; 10:e23743.

Zhang X, Fu X, Ren Z, Zhou X, Ma Q: Relationship between thrombus composition and prognosis in patients with acute ischemic stroke undergoing mechanical thrombectomy. *J Clin Neurosci* 2024b; 126:46-51.

Zhong K, An X, Kong Y, Chen Z: Predictive model for the risk of hemorrhagic transformation after rt-PA intravenous thrombolysis in patients with acute ischemic stroke: A systematic review and metaanalysis. *Clin Neurol Neurosurg* 2024; 239:108225.

Zhou T, Yi T, Li T, Zhu L, Li Y, Li Z, Wang M, Li Q, He Y, Yang P, Zhang Y, Li Z, Zhang Y, Ye X, Chen W, Wang S, Liu J, Investigators D-MR: Predictors of futile recanalization in patients undergoing endovascular treatment in the DIRECT-MT trial. *J Neurointerv Surg* 2022; 14:752-755.

Zubair AS, Sheth KN: Hemorrhagic Conversion of Acute Ischemic Stroke. *Neurotherapeutics* 2023; 20:705-711.

Zuin M, Mazzitelli M, Rigatelli G, Bilato C, Cattelan AM: Risk of ischemic stroke in patients recovered from COVID-19 infection: A systematic review and meta-analysis. *Eur Stroke J* 2023; 8:915-922.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.01.24316555;](https://doi.org/10.1101/2024.11.01.24316555) this version posted November 4, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .